These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28914736)

  • 41. [Neuropathology of tauopathy].
    Yoshida M
    Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
    Hauw JJ; Hausser-Hauw C; Duyckaerts C
    Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tauopathies.
    Kovacs GG
    Handb Clin Neurol; 2017; 145():355-368. PubMed ID: 28987182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes of Cerebrospinal Fluid Peptides due to Tauopathy.
    Majerova P; Barath P; Michalicova A; Katina S; Novak M; Kovac A
    J Alzheimers Dis; 2017; 58(2):507-520. PubMed ID: 28453489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.
    Zilka N; Korenova M; Novak M
    Acta Neuropathol; 2009 Jul; 118(1):71-86. PubMed ID: 19238406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.
    Feuillette S; Miguel L; Frébourg T; Campion D; Lecourtois M
    J Neurochem; 2010 May; 113(4):895-903. PubMed ID: 20193038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tau pathology in diabetes mellitus.
    Wu J; Nie SD; Wang S
    Pharmazie; 2013 Aug; 68(8):649-52. PubMed ID: 24020118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical features and survival of 3R and 4R tauopathies presenting as behavioral variant frontotemporal dementia.
    Hu WT; Parisi JE; Knopman DS; Boeve BF; Dickson DW; Ahlskog JE; Petersen RC; Josephs KA
    Alzheimer Dis Assoc Disord; 2007; 21(4):S39-43. PubMed ID: 18090422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
    Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
    Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tau-imaging in neurodegeneration.
    Bischof GN; Endepols H; van Eimeren T; Drzezga A
    Methods; 2017 Nov; 130():114-123. PubMed ID: 28790016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Threonine
    Moszczynski AJ; Yang W; Hammond R; Ang LC; Strong MJ
    Acta Neuropathol Commun; 2017 Jan; 5(1):6. PubMed ID: 28077166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.
    Trzeciakiewicz H; Tseng JH; Wander CM; Madden V; Tripathy A; Yuan CX; Cohen TJ
    Sci Rep; 2017 Mar; 7():44102. PubMed ID: 28287136
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies.
    Orr ME; Sullivan AC; Frost B
    Trends Pharmacol Sci; 2017 Jul; 38(7):637-648. PubMed ID: 28455089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tau Diagnostics and Clinical Studies.
    Gozes I; Höglinger G; Quinn JP; Hooper NM; Höglund K
    J Mol Neurosci; 2017 Oct; 63(2):123-130. PubMed ID: 29082468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of Tau protein in long COVID and potential therapeutic targets.
    Marwaha B
    Front Cell Infect Microbiol; 2023; 13():1280600. PubMed ID: 37953801
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Xenobiotics, Trace Metals and Genetics in the Pathogenesis of Tauopathies.
    Aaseth J; Buha A; Wallace DR; Bjørklund G
    Int J Environ Res Public Health; 2020 Feb; 17(4):. PubMed ID: 32079163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-tau antibodies: hitting the target.
    Golde TE; Lewis J; McFarland NR
    Neuron; 2013 Oct; 80(2):254-6. PubMed ID: 24139027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of tauopathy research funding between 2006 and 2016 reveals critical gaps in research priorities.
    Altimus CM; Keller K; Brannelly P; Ross E; Lin CT; Riley EAU; Briggs L; Smith J; Stevens M
    Alzheimers Dement; 2019 Jan; 15(1):42-54. PubMed ID: 30314799
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.
    Sigurdsson EM
    J Alzheimers Dis; 2018; 64(s1):S555-S565. PubMed ID: 29865056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tau Filaments and the Development of Positron Emission Tomography Tracers.
    Goedert M; Yamaguchi Y; Mishra SK; Higuchi M; Sahara N
    Front Neurol; 2018; 9():70. PubMed ID: 29497399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.